

AF\$1644

ATTENTION: BOX AFTER FINAL  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1600

PATENT  
Attorney Docket No. 2481.1337-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

Mathias GEHRMANN et al.

Serial No.: 08/989,896

Filed: December 12, 1997

For: FUSION PROTEINS FOR  
PRODRUG ACTIVATION



) Group Art Unit: 1644

) Examiner: D. Saunders

) Attention: BOX AFTER FINAL

RECEIVED

JAN 09 2001

TECH CENTER 1600/2904

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

AMENDMENT AFTER FINAL

In response to the Final Office Action of August 7, 2000, and pursuant to  
37 C.F.R. § 1.116, Applicants propose that this application be amended as follows:

IN THE CLAIMS:

Please amend claims 1, 2, 3, 29, and 30 as follows:

1. (Thrice Amended) A compound comprising [an] at least one antigen binding region linked to at least one prodrug-activating enzyme, where the antigen binding [region] region(s) is composed of a single polypeptide chain, and where the antigen binding region has a bivalent or a multivalent structure.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNN, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202 408 4000